The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) is a huge mover today! About 167,111 shares traded hands. Flexion Therapeutics Inc (NASDAQ:FLXN) has risen 37.27% since April 21, 2016 and is uptrending. It has outperformed by 31.94% the S&P500.
The move comes after 5 months positive chart setup for the $576.56 million company. It was reported on Nov, 23 by Barchart.com. We have $19.72 PT which if reached, will make NASDAQ:FLXN worth $40.36 million more.
Analysts await Flexion Therapeutics Inc (NASDAQ:FLXN) to report earnings on March, 9. They expect $-0.75 EPS, down 19.05% or $0.12 from last year’s $-0.63 per share. After $-0.65 actual EPS reported by Flexion Therapeutics Inc for the previous quarter, Wall Street now forecasts 15.38% negative EPS growth.
Flexion Therapeutics Inc (NASDAQ:FLXN) Ratings Coverage
Out of 7 analysts covering Flexion Therapeutics (NASDAQ:FLXN), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Flexion Therapeutics has been the topic of 7 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Lake Street on Thursday, July 21. On Wednesday, June 29 the stock rating was initiated by BMO Capital Markets with “Outperform”. Wells Fargo reinitiated Flexion Therapeutics Inc (NASDAQ:FLXN) on Tuesday, May 3 with “Outperform” rating. The rating was initiated by Cantor Fitzgerald with “Buy” on Wednesday, November 4. The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) has “Buy” rating given on Wednesday, September 9 by Needham.
According to Zacks Investment Research, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.54 in Q2 2016. Its down 1.31, from 2.85 in 2016Q1. The ratio is negative, as 9 funds sold all Flexion Therapeutics Inc shares owned while 11 reduced positions. 21 funds bought stakes while 36 increased positions. They now own 18.68 million shares or 38.37% more from 13.50 million shares in 2016Q1.
Driehaus Ltd Liability Corp holds 0.48% or 891,274 shares in its portfolio. Natl Bank Of New York Mellon Corp accumulated 0.01% or 1.59M shares. Highbridge Cap Ltd Liability Corp has invested 0.01% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN). Moreover, Tpg Group Inc (Sbs) Advisors Inc has 0.12% invested in Flexion Therapeutics Inc (NASDAQ:FLXN) for 714,285 shares. Teachers has 0% invested in the company for 29,707 shares. Geode Capital Mngmt Llc has invested 0% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN). Manufacturers Life Ins Com The reported 13,545 shares or 0% of all its holdings. Victory Cap Mngmt last reported 1,214 shares in the company. Wells Fargo Mn, a California-based fund reported 866,248 shares. The Colorado-based Alps Advsr has invested 0% in Flexion Therapeutics Inc (NASDAQ:FLXN). Macquarie Grp last reported 0% of its portfolio in the stock. Barclays Public Limited Com last reported 0% of its portfolio in the stock. Bnp Paribas Arbitrage Sa holds 734 shares or 0% of its portfolio. Wasatch last reported 835,781 shares in the company. Moreover, Commonwealth Equity Service Incorporated has 0% invested in Flexion Therapeutics Inc (NASDAQ:FLXN) for 16,767 shares.
Insider Transactions: Since June 8, 2016, the stock had 7 buys, and 0 insider sales for $30.67 million net activity. 1,666 shares were bought by Clayman Michael D., worth $29,900 on Tuesday, November 22. Shares for $599,994 were bought by COLELLA SAMUEL D. Shares for $10.00M were bought by LUBASH BARBARA N on Wednesday, June 8. Another trade for 1,000 shares valued at $13,387 was bought by MERRIFIELD C ANN. Another trade for 714,285 shares valued at $10.00M was bought by Versant Ventures III – LLC.
More recent Flexion Therapeutics Inc (NASDAQ:FLXN) news were published by: Fool.com which released: “Why Shares of Flexion Therapeutics, Inc., Lantheus Holdings Inc, and PDL …” on November 16, 2016. Also Fool.com published the news titled: “Can Flexion Therapeutics Add Some Muscle to Your Portfolio?” on November 17, 2016. Finance.Yahoo.com‘s news article titled: “Flexion Therapeutics reports 3Q loss” with publication date: November 07, 2016 was also an interesting one.
FLXN Company Profile
Flexion Therapeutics, Inc., incorporated on November 5, 2007, is a specialty pharmaceutical company. The Firm is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain. The Company’s lead product candidate, Zilretta (also known as FX006), is a late-stage, injectable, sustained-release, intra-articular (IA) steroid for patients with moderate to severe OA pain. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Firm has not generated any revenue.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.